Art

J-GLOBAL ID：201502223393976649   Reference number：15A0304060

注目の新薬 レゴラフェニブ(スチバーガ錠40mg)

Author (6)： YAMAGUCHI KENSEI (埼玉県がんセ 消化器内科) ,  YAMADA SUKIKO (埼玉県がんセ 消化器内科) ,  HARA HIROKI (埼玉県がんセ 消化器内科) ,  YOSHII TAKAKO (埼玉県がんセ 消化器内科) ,  ASAYAMA MASAKO (埼玉県がんセ 消化器内科) ,  NAKAYAMA TOSHIAKI (埼玉県がんセ 薬剤部)
Material： 診断と治療  (Diagnosis and Treatment)
Volume： 103  Issue： 2  Page： 265-271  Publication year： Feb. 01, 2015 
JST Material Number： Z0941A  ISSN： 0370-999X  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *antitumor drug ,...
Semi thesaurus term： GIST ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0304060&from=J-GLOBAL&jstjournalNo=Z0941A") }}

JST classification (4)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Tumors(=neoplasms)of digestive system  (GH04000D) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Clinical application of enzyme preparations and inhibitor preparations  (GW21020H)

Substance index (1)： Regorafenib

Reference (7)：

• Mross K, et al. : A phase I dose-escalation study of regorafenib (BAY 73-4506) , an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18 :2658-2667, 2012
• Sunakawa Y, et al. : Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs 32:104-112, 2014
• De Wit M, et al.: Prevention and management of adverse events related to regorafenib. Support Care Cancer 22:837-846, 2014
• Grothey A, et al.: Optimizing treatment outcomes with regorafenib : personalized dosing and other strategies to support patient care. Oncologist 19:669-680, 2014
• Grothey A, et al. ; CORRECT Study Group. :Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 381:303-312, 2013

Terms in the title (4)： 注目 ,  新薬 ,  レゴラフェニブ ,  スチバーガ